RPL18 and neoplasm: Importantly, the combination of CD3xTRP1 with tumor-nonspecific OVA, as well as the tumor-specific neoantigen Rpl18 SLP22 vaccines adjuvanted with CpG, both resulted in complete antitumor responses in almost all mice (Fig. 7e).